
Dual Integrin And Grpr Targeted Radiotherapy Of Prostate CancerAward last edited on: 6/5/09
Sponsored Program
SBIRAwarding Agency
NIH : NCITotal Award Amount
$100,000Award Phase
1Solicitation Topic Code
-----Principal Investigator
Jenny C WuCompany Information
Acaduceus Pharmaceutics Inc
11171 Bubb Road
Cupertino, CA 95014
Cupertino, CA 95014
(408) 306-5635 |
jennywu@acaduceuspharma.com |
www.acaduceuspharma.com |
Location: Single
Congr. District: 18
County: Santa Clara
Congr. District: 18
County: Santa Clara
Phase I
Contract Number: 1R43CA139678-01Start Date: 4/1/09 Completed: 10/31/09
Phase I year
2009Phase I Amount
$100,000Public Health Relevance:
We will develop the novel clinically translatable dual integrin and GRPR targeted radiotherapy of prostate cancer. Because the agent targets preferentially to specific receptors on cancer cells, we anticipate that the new tracers for radiotherapy will have better efficacy and reduced peripheral toxicity. The same strategy should also be applicable to other cancer therapeutics.
Public Health Relevance:
We will develop the novel clinically translatable dual integrin and GRPR targeted radiotherapy of prostate cancer. Because the agent targets preferentially to specific receptors on cancer cells, we anticipate that the new tracers for radiotherapy will have better efficacy and reduced peripheral toxicity. The same strategy should also be applicable to other cancer therapeutics.
Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00